This activity is part of the Frankly Speaking with Dr. Frank Domino podcast series.
Podcast
Statins and the Older Population: When Is It Beneficial and When Is It Not? - Frankly Speaking EP 96Evidence of the efficacy of statins to reduce ASCVD morbidity and mortality in individuals > 75 years who have known clinical ASCVD (secondary prevention) is well established. Primary prevention in this population has not been as clear. Join us while we discuss a recent study in the BMJ which assessed the benefits of statins for primary prevention of ASCVD morbidity and mortality in individuals > 75 years with and without DM.
Guest: Susan Feeney, DNP, FNP-BC
Evidence of the efficacy of statins to reduce ASCVD morbidity and mortality in individuals > 75 years who have known clinical ASCVD (secondary prevention) is well established. Primary prevention in this population has not been as clear. Join us while we discuss a recent study in the BMJ which assessed the benefits of statins for primary prevention of ASCVD morbidity and mortality in individuals > 75 years with and without DM.
CME Information
0 Credits - Not for CME/CE Credit
Release Date: 11/26/2018
Expiration Date: 12/31/2099
Topics
Faculty
Learning Objectives
Faculty Disclosures
Frank J. Domino, MD
Learn More
Resources
- Ramos, R. et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. BMJ 2018;362:k3359, http://dx.doi.org/10.1136/bmj.k3359
- Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1–S45.
- US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults, US Preventive Services Task Force Recommendation Statement. JAMA. 2016;316(19):1997–2007. doi:10.1001/jama.2016.15450